NASDAQ · VERV
Verve Therapeutics, Inc.
$11.13+$0.03 (+0.27%)
Verve Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
Loading market information…
NASDAQ · HARP · USD
Stock price, earnings
Quote as of Mar 8, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Harpoon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Harpoon Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:49 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 10, 2022 |
| -$5.30+3.64% vs estimate |
| $8.30M |
| Q1 2022 | May 12, 2022 | -$6.20-29.17% vs estimate | $5.91M+14.58% vs estimate |
|---|
KEEP COMPARING
$11.13+$0.03 (+0.27%)
Verve Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
$44.15$0.00 (0.0%)
Albireo Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.39% below the high.
$8.54$0.00 (0.0%)
Chimerix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$12.49$0.00 (0.0%)
Avid Bioservices, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.16% below the high.
$19.00+$0.04 (+0.21%)
Intercept Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.08% below the high.
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$15.31-$0.14 (-0.91%)
Icosavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
